Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Advertisement

Experimental & Molecular Medicine
  • View all journals
  • Search
  • My Account Login
  • Content Explore content
  • About the journal
  • Publish with us
  • Sign up for alerts
  • RSS feed
  1. nature
  2. experimental & molecular medicine
  3. articles
  4. article
IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1
Download PDF
Download PDF
  • Article
  • Open access
  • Published: 01 August 2004

IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1

  • Su-Jin Yu1,
  • Hyeon Soo Kim,
  • Sung-Won Cho &
  • …
  • Jeongwon Sohn 

Experimental & Molecular Medicine volume 36, pages 372–379 (2004)Cite this article

  • 932 Accesses

  • 22 Citations

  • 1 Altmetric

  • Metrics details

Abstract

Interleukin (IL)-4 inhibits proliferation of several human cancer cell lines in vitro. Although IL-4 is known to regulate proliferation of lymphocytes by modulating p27KIP1 expression, the mechanism involved in the IL-4-induced growth inhibition of nonhematopoietic cancer cells has not been fully elucidated. Previously, we reported that IL-4 suppressed proliferation of human renal cell carcinoma (RCC) cell lines in vitro. Here, we show that IL-4 inhibits cell cycle progression at the G1 phase in Caki-1 cells by increasing the expression of p21WAF1 and interferon regulatory factor (IRF)-1, and decreasing the cyclin dependent kinase (CDK) 2 activity. Up-regulation of p21WAF1 and IRF-1 expression is transcriptional, but independent of p53. The levels of p21WAF1 and IRF-1 proteins were enhanced as early as 1 h after IL-4 treatment. CDK2 activity started to decline at 4 h after IL-4 treatment, and by 24 h, was ~50% of the control. Neither the protein expressions of p27KIP1 and p16INK4a, nor the phosphorylation level of pRb was changed. The importance of p21WAF1 and IRF-1 in the growth inhibition induced by IL-4 was confirmed by antisense oligonucleotide transfection. Both of p21WAF1 and IRF-1 antisense oligonucleotides prevented IL-4-mediated growth inhibition by ~30% compared to the respective sense oligonucleotides. In summary, our study indicated that p21WAF1 and IRF-1 mediate the growth inhibitory effect of IL-4 in human RCC cells.

Similar content being viewed by others

Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma

Article 17 November 2021

IRF4 drives clonal evolution and lineage choice in a zebrafish model of T-cell lymphoma

Article Open access 03 May 2022

Prognostic and therapeutic relevance of IL2RG-related LncRNAs in clear cell renal cell carcinoma

Article Open access 13 August 2025

Article PDF

Author information

Authors and Affiliations

  1. Department of Biochemistry College of Medicine, Korea University, Seoul, 136-705, Korea

    Su-Jin Yu

Authors
  1. Su-Jin Yu
    View author publications

    Search author on:PubMed Google Scholar

  2. Hyeon Soo Kim
    View author publications

    Search author on:PubMed Google Scholar

  3. Sung-Won Cho
    View author publications

    Search author on:PubMed Google Scholar

  4. Jeongwon Sohn
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Yu, SJ., Kim, H., Cho, SW. et al. IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1. Exp Mol Med 36, 372–379 (2004). https://doi.org/10.1038/emm.2004.49

Download citation

  • Published: 01 August 2004

  • Issue date: 01 August 2004

  • DOI: https://doi.org/10.1038/emm.2004.49

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

  • IL-4
  • interferon regulatory factor-1
  • p21WAF1
  • renal cell carcinoma

This article is cited by

  • Interleukin-4 gene intron 3 VNTR polymorphism in adult acute myeloid leukemia

    • Nesma A. Safwat
    • Marwa R. El Najjar
    • Haydi S. Mohamed

    Egyptian Journal of Medical Human Genetics (2022)

  • DNA-double strand breaks enhance the expression of major histocompatibility complex class II through the ATM-NF-κΒ-IRF1-CIITA pathway

    • Tsukasa Oda
    • Ruri Nakamura
    • Takayuki Yamashita

    Cancer Gene Therapy (2022)

  • Association between interleukin-4 gene intron 3 VNTR polymorphism and cancer risk

    • Yin Duan
    • Chi Pan
    • Suzhan Zhang

    Cancer Cell International (2014)

  • IL-4 inhibits the TNF-α induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-α to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses

    • Claudia Falkensammer
    • Karin Jöhrer
    • Martin Thurnher

    Cancer Immunology, Immunotherapy (2006)

Download PDF

Advertisement

Explore content

  • Research articles
  • Reviews & Analysis
  • News & Comment
  • Current issue
  • Collections
  • Sign up for alerts
  • RSS feed

About the journal

  • Special Feature
  • Journal Information
  • About the Editors
  • About the Partner
  • Contact
  • For Advertisers
  • Press Releases
  • Open Access Fees and Funding

Publish with us

  • For Authors & Referees
  • Language editing services
  • Submit manuscript

Search

Advanced search

Quick links

  • Explore articles by subject
  • Find a job
  • Guide to authors
  • Editorial policies

Experimental & Molecular Medicine (Exp Mol Med)

ISSN 2092-6413 (online)

ISSN 1226-3613 (print)

nature.com sitemap

About Nature Portfolio

  • About us
  • Press releases
  • Press office
  • Contact us

Discover content

  • Journals A-Z
  • Articles by subject
  • protocols.io
  • Nature Index

Publishing policies

  • Nature portfolio policies
  • Open access

Author & Researcher services

  • Reprints & permissions
  • Research data
  • Language editing
  • Scientific editing
  • Nature Masterclasses
  • Research Solutions

Libraries & institutions

  • Librarian service & tools
  • Librarian portal
  • Open research
  • Recommend to library

Advertising & partnerships

  • Advertising
  • Partnerships & Services
  • Media kits
  • Branded content

Professional development

  • Nature Awards
  • Nature Careers
  • Nature Conferences

Regional websites

  • Nature Africa
  • Nature China
  • Nature India
  • Nature Japan
  • Nature Middle East
  • Privacy Policy
  • Use of cookies
  • Legal notice
  • Accessibility statement
  • Terms & Conditions
  • Your US state privacy rights
Springer Nature

© 2025 Springer Nature Limited